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Interfering with the inhibitory mechanism of serpins: crystal
structure of a complex formed between cleaved plasminogen
activator inhibitor type 1 and a reactive-centre loop peptide
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Djordje Musil2, Lennart Sjölin1 and Johanna Deinum3*
Background: Plasminogen activator inhibitor type 1 (PAI-1) is an important
endogenous regulator of the fibrinolytic system. Reduction of PAI-1 activity has
been shown to enhance dissolution of blood clots. Like other serpins, PAI-1
binds covalently to a target serine protease, thereby irreversibly inactivating the
enzyme. During this process the exposed reactive-centre loop of PAI-1 is
believed to undergo a conformational change becoming inserted into β sheet A
of the serpin. Incubation with peptides from the reactive-centre loop transform
serpins into a substrate for their target protease. It has been hypothesised that
these peptides bind to β sheet A, thereby hindering the conformational
rearrangement leading to loop insertion and formation of the stable
serpin–protease complex.
Results: We report here the 1.95 Å X-ray crystal structure of a complex of a
glycosylated mutant of PAI-1, PAI-1-Ala335Glu, with two molecules of the
inhibitory reactive-centre loop peptide N-Ac-TVASS-NH2. Both bound peptide
molecules are located between β strands 3A and 5A of the serpin. The binding
kinetics of the peptide inhibitor to immobilised PAI-1-Ala335Glu, as monitored
by surface plasmon resonance, is consistent with there being two different
binding sites.
Conclusions: This is the first reported crystal structure of a complex formed
between a serpin and a serpin inhibitor. The localisation of the inhibitory peptide
in the complex strongly supports the theory that molecules binding in the space
between β strands 3A and 5A of a serpin are able to prevent insertion of the
reactive-centre loop into β sheet A, thereby abolishing the ability of the serpin to
irreversibly inactivate its target enzyme. The characterisation of the two binding
sites for the peptide inhibitor provides a solid foundation for computer-aided
design of novel, low molecular weight PAI-1 inhibitors.
Introduction
Plasminogen activator inhibitor type 1 (PAI-1) is a member
of the serine protease inhibitor (serpin) superfamily. Serpins
inactivate their target proteases by forming equimolar com-
plexes, which do not dissociate in the presence of sodium
dodecyl sulphate (SDS) [1]. PAI-1 irreversibly inactivates
tissue- and urokinase-type plasminogen activator (tPA and
uPA) [2], resulting in decreased fibrinolytic activity. PAI-1
is therefore thought to have important roles in the devel-
opment of thromboembolic diseases, atherosclerosis and
maybe also tumour invasion and metastasis. Pharmaceutical
reduction of PAI-1 activity [3] might therefore offer sub-
stantial clinical benefits.
The recently reported three-dimensional structures of
two intact serpins, antichymotrypsin and antithrombin
III [4–6], localise the cleavage site for the protease to the
peptide bond between the residues Arg346 (P1) and
Met347 (P1′) the P1–P1′ residues of an active serpin to a
mobile ‘reactive-centre’ loop of amino acids, protruding
from the main body of the protein (Figure 1). This
exposed loop is thought to act as a ‘bait’ for the target
protease [1,7].
In vitro, wild-type PAI-1 can exist in at least three con-
formations: active, substrate and latent (inactive). Active
PAI-1 spontaneously converts into latent PAI-1 [2]. Active
PAI-1 forms a tight, presumably covalent, complex with
tPA in which PAI-1 is cleaved at the P1–P1′ peptide
bond [8]. So far the structural features of the PAI-1–tPA
complex remain uncertain, but recent results from fluores-
cence energy transfer experiments [9–11] and antibody
mapping [12] have provided some insight into the posi-
tioning of the two proteins in relation to each other. In
contrast, it is known that the substrate form of PAI-1 is
rapidly cleaved by tPA at the P1–P1′ peptide bond but
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the complex then dissociates [13–16]. The latent form of
PAI-1 is devoid of inhibitory activity due to a complete
rearrangement of the reactive-centre loop [17]. 
In the structure of latent PAI-1 the P16–P4 portion of the
loop has been found to be inserted between β strands 3
and 5 of the antiparallel β sheet A [17] (Figure 1), while in
the structure of a cleaved PAI-1 mutant, PAI-1-Ala335Pro,
the P16–P3 portion is inserted [18,19]. However, as there
is still no crystal structure of active PAI-1 available, it
remains uncertain whether the reactive-centre loop in
active PAI-1 is partially inserted or completely exposed
[1]. It has also been debated whether it is the position of
this loop, or differences in the rate of loop insertion, that
governs the substrate behaviour of a serpin [1,7].
Several studies have revealed that point mutations in the
highly conserved reactive-centre loop have a profound
influence on protease specificity, stability and inhibitory
versus substrate behaviour of serpins [1,7]. It has been
shown that both PAI-1 and some other serpins lose their
inhibitory activity and become substrates for their target
proteases when bulky or charged residues at the P12
position are introduced [13,16,20]. Moreover, Ala335 at
P12 is the only completely conserved reactive-centre
residue among all inhibitory serpins [1]. Consequently,
the obstruction of the insertion of this loop at residue
P12 apparently at some stage blocks the path leading
from an initial Michaelis-like complex to the final stable
acyl-enzyme complex [21].
The interspace between the upper part of β strand 3A and
5A therefore constitutes an attractive binding site for
inhibitors of serpin activity. Peptides containing fragments
of the reactive-centre loop have indeed been proved to
inhibit α1-antitrypsin and antithrombin [22,23]. Moreover,
the peptides corresponding to P14–P1 (TVASSSTA-
VIVSAR) and P14–P7 (TVASSSTA) in PAI-1 have been
shown to inhibit PAI-1 activity [24,25]. In most cases the
peptides transform the active serpin into a substrate for its
target protease. We have, in addition, found that a smaller
fragment of the reactive-centre loop inhibits PAI-1 activity
and transform PAI-1 into a tPA substrate. In this report we
present the crystal structure of the complex of the capped
pentapeptide N-Ac-Thr-Val-Ala-Ser-Ser-NH2 (TVASS)
with the cleaved P12 mutant PAI-1-Ala335Glu. The crystal
structure confirms that one peptide, as predicted, does
indeed occupy the same space in PAI-1-Ala335Glu that the
P14–P10 residues of β strand 4A occupy in latent [17] and
cleaved PAI-1-Ala335Pro [18,19], while the second peptide
occupies the same space as residues P6–P2 of the cleaved
loop in PAI-1-Ala335Pro.
In conclusion, this is the first reported structure of a
complex formed between a low molecular weight com-
pound and a serpin. The present crystal structure also
has one of the highest resolutions of the reported serpin
structures, comparable to that found for an inactive serpin,
ovalbumin [26]. Moreover, for the first time two of the
three possible glycosylation sites in the PAI-1 protein
could be identified.
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Figure 1
The structures of latent and active PAI-1. 
(a) Schematic model of latent PAI-1 [17] and
(b) a constructed model of active PAI-1 [16]
based on the structures of both latent PAI-1
and antithrombin III [38] with some important
structural domains indicated. The protein is
shown from the front with the β sheet A
coloured red; β strands 3A to 5A are
indicated. (The figure was prepared using the
program MOLSCRIPT [39].)
Results and discussion
Crystal structure
The parameters and statistics from the data collection and
the structure refinement are collected in Table 1. The
refined model of cleaved PAI-1-Ala335Glu in complex
with two pentapeptides includes 3099 non-hydrogen atoms,
69 waters and four sugar molecules. The overall structure
of PAI-1-Ala335Glu closely resembles that of cleaved
PAI-1-Ala335Pro (with a proline at P12) [18,19]. The root
mean square (rms) deviation of the topologically equiva-
lent α-carbon atoms of these two structures, excluding β
strand 4A, was 1.3 Å (Figure 2). Additional exclusion of
some flexible loops from this comparison resulted in an
rms deviation of 0.7 Å for the Cα atoms.
In the final model of the complex the segment Val334
(P13) to Met347 (P1′) has been removed from the protein
model because of the lack of interpretable electron
density in the Fourier map for these residues. Moreover,
complementary studies (see below) have shown that this
PAI-1 mutant had been exclusively cleaved at the P1–P1′
position. In the present model (Figure 3), four terminal
residues are therefore present, His2 and Pro379 as
expected from other closely related crystal structures and
the terminal residues Thr333 (P14) and Ala348 (P2′). Fur-
thermore, in the complex the remaining residues from P13
to Ser331 (P16) are not directed into β sheet A, as in latent
PAI-1, but point away from the molecule body towards
the solvent. However, Gly332 (P15) and Thr333 (P14) are,
in spite of their slightly elevated B factors, well defined in
the Fourier electron-density map.
In latent PAI-1, 13 residues of the reactive-centre loop
(P16–P4) are inserted into β sheet A forming the integral
β strand 4A. The residues of this strand make numerous
hydrogen bonds with β strands 3A and 5A [17]. These
hydrogen bonds may contribute to the stability of the
latent PAI-1 structure. In the position between the
β strands 3A and 5A, two TVASS molecules are found in
our crystal structure of PAI-1-Ala335Glu (Figures 3 and 4).
The first pentapeptide occupies the same space as the
residues P14–P10 (TVASS) both in latent PAI-1 and
cleaved PAI-1-Ala335Pro [18,19]. The second peptide
occupies the same space as residues P6–P2 in cleaved
PAI-1-Ala335Pro (Figures 3–5). The break in the electron
density between these two pentapeptides remained
throughout the entire course of the structure refinement,
and in addition, the electron density always indicated the
sequence TVASS instead of the P6–P2 sequence VIVSA
(Figure 4). Apart from the above differences between the
structure of the cleaved PAI-1-Ala335Glu complex and
cleaved PAI-1-Ala335Pro, there are some minor changes
in the loops connecting the well defined secondary struc-
ture elements (Figure 2) indicating conformational flexi-
bility at these positions. These changes are, however,
probably related to crystal-packing effects. 
Another area of interest in the structure is at the plausi-
ble binding site for two types of low molecular weight
inhibitors [3,16], in the proximity of the binding epitope
for the strongly inhibiting monoclonal antibody CLB-2C8.
In this area conformational differences in active PAI-1
compared to latent PAI-1 have been postulated previously
[16]. In the same environment, around residues 76 in helix
D and 115 in helix E (Figure 3), there are unexpected
deviations between the structures of latent PAI-1 and the
PAI-1-Ala335Glu complex (Figure 2). These deviations
may however also depend on crystal-packing effects.
The sequence of PAI-1 contains three possible N-glycosy-
lation sites consistent with the Asn-X-Thr/Ser pattern. In
the structure of the PAI-1-Ala335Glu mutant, sugar mol-
ecules are identified at two of these positions (Figure 3).
The first glycan is linked to Asn209, where only one carbo-
hydrate molecule is visible and subsequently built into the
model as N-acetyl-β-D-glucosamine (GlcNAc). The second
glycosylation site, Asn265 (Figure 6), has a better defined
carbohydrate chain with three sugar molecules defined in
the electron density. This glycan is branched after the first
GlcNAc having possibly one (1→4) linked GlcNAc and
one (1→6) linked D-mannose. The third potential glycosy-
lation site at Asn329 is strategically located on strand 5 of
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Table 1
Parameters and statistics from the data collection and
refinement of PAI-1-Ala335Glu in complex with two molecules
of TVASS.
Unit cell constants (Å) 63.1, 83.4, 101.8
Space group P212121
No. of molecules in asymmetric unit 1
No. of measurements 190,702
No. of unique reflections 40,129
Data completeness (%)
sigma cut-off –3* 99.7 (99.7)*
sigma cut-off 0* 95.8 (89.6)*
sigma cut-off 2* 82.1 (55.2)*
Rmerge† 0.067 (0.368)*
No. of atoms in refined model 3099
No. of atoms in protein 2909
No. of atoms in ligands 70
No. of atoms in carbohydrates 51
No. of atoms in solvent 69
Resolution range in refinement (Å) 38.6–1.95
Rms deviation
bond length (Å) 0.007
angles (°) 1.366
Rcryst‡ 0.181
Rfree 0.210
Estimated error of coordinates (Å)§ 0.24
*Numbers in parentheses refer to the values for the outer shell.
†Rmerge = ΣhΣi (I(h,i) – < I(h) >) / ΣhΣi I(h,i), where I(h,i) is the intensity
value of the ith measurement of h and < I(h) > the corresponding
mean value of h for all i measurements of h. ‡Rcryst = Σhkl(|Fo–Fc|) /
Σhkl |Fo|, where |Fo| and |Fc| are the observed and calculated
structure-factor amplitudes, respectively. §Determined using the
cross-validation Luzzati method.
β sheet A (Figure 3), and the presence of glycosylation at
this position might be responsible for steric or charge effects
at the insertion site [16]. Preliminary results J Ehnebom
and JD, unpublished results) did reveal differences in the
effect of TVASS on unglycosylated compared with glycosy-
lated PAI-1, supporting the presence of glycosylation at this
position. This site did, however, not reveal any electron
density and, if glycosylation is present at this site, the sugar
must have been very disordered. 
Finally, a Ramachandran plot (Figure 7) shows that 99.7%
of the residues lie in the most favoured or additionally
allowed regions, based on analysis of 118 structures with a
resolution of at least 2.0 Å and an R factor no greater than
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Figure 3
Structure of the complex of PAI-1-Ala335Glu
with two bound TVASS molecules. The N-
and C-terminal residues are indicated. Green
triangles represent the positions of identified
sugar molecules, the white triangle represents
the potential third glycosylation site. The
reported position of the binding site for low
molecular weight inhibitors [16] at Arg115
and Arg76 is indicated (blue circles). The
β sheet A is coloured red. (a) Front view; (b)
view after 90° rotation about the vertical axis.
Residues Val334–Met347 have not been
identified in the electron-density map. (The
figure was prepared using MOLSCRIPT [39].)
Figure 2
Delta plots illustrating the secondary structure
elements. The magenta trace shows the
average isotropic B factors per residue for the
refined structure of the complex of
PAI-1-Ala335Glu with two TVASS molecules
(residues Val334–Met347 have not been
identified). The other two traces represent the
root mean square (rms) deviations with latent
PAI-1 (green trace) [17] or cleaved PAI-1-
Ala335Pro (black trace) [18]. The different
domains of the structures are indicated
underneath.
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20%. A good quality model would be expected to have over
90% in the most favoured regions. Only one residue, Lys88,
is found in the disallowed region. This residue, which has a
well defined electron density, is in a turn region positioned
between a one-turn 310 helix and the β strand 2A. 
Enhancement of the substrate properties of PAI-1-Ala335Glu
The stable mutant PAI-1-Ala335Glu has previously been
proposed as, and shown to be, a substrate for tPA [16].
The binding course of tPA to captured wild-type PAI-1
monitored by surface plasmon resonance (SPR), using
BIAcore technology, can be characterised by a very
rapid association phase and the formation of a stoichio-
metric stable complex [27]. In the absence of TVASS,
tPA binds initially to PAI-1-Ala335Glu, but rapidly disso-
ciates again from the immobilised protein [16], consis-
tent with its substrate character. However, in the pres-
ence of TVASS the same general picture was seen, but
both the binding and the dissociation of tPA were appar-
ently more rapid (Figure 8) suggesting an enhanced sub-
strate character of PAI-1-Ala335Glu. Moreover, in the
presence of TVASS, wild-type PAI-1 was converted from
an irreversible inhibitor into a substrate for tPA.
In the absence of TVASS, PAI-1-Ala335Glu has been
found to be stable at room temperature for several weeks
both at pH 5.5 [16] and pH 7.4. After the PAI-1 mutant
was incubated with TVASS for 1 h at room temperature,
analysis by SDS polyacrylamide gel electrophoresis still
only showed the full-length protein (47 kDa), as also con-
firmed by matrix-assisted laser desorption mass spectro-
metry (MALDI). However, as shown by both these tech-
niques, after overnight incubation of PAI-1-Ala335Glu
with TVASS, the protein was completely cleaved, sug-
gesting the presence of protease contamination. We have
shown before that catalytic amounts of tPA rapidly cleave
PAI-1-Ala335Glu [16]. However, the addition of a cock-
tail of protease inhibitors was unable to prevent the cleav-
age during incubation with TVASS. The mutant was
exclusively cleaved at the P1–P1′ site (Arg346–Met347)
as confirmed by the appearance of the terminal 3804 Da
moiety [8] and the absence of other fragments. Dissolved
crystals of PAI-1-Ala335Glu in complex with TVASS were
shown to be similarly cleaved. Preliminary results utilising
two-dimensional gel electrophoresis showed a pattern of
peptides that is typical of glycosylated proteins. In addition,
the cleavage pattern was the same with PAI-1-Ala335Glu
Research Article  Structure of a serpin–inhibitor complex Xue et al. 631
Figure 4
Stereo view of the electron-density map
(2Fo–Fc map, contoured at 1.2σ) calculated
from the refined model, showing part of the
major β sheet A. The red dots outside the
densities are water molecules. The missing
density for one of the water molecules is due
to the elevated contour level used for clarity of
the figure. The two bound TVASS peptides
have been labelled as residues 901–905 and
911–915.
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Structure
and TVASS, as observed if PAI-1-Ala335Glu had been
incubated with catalytic amounts of tPA.
Binding of TVASS to immobilised PAI-1-Ala335Glu
The binding kinetics of TVASS to immobilised PAI-1-
Ala335Glu was determined by SPR (Figure 9). Evaluation
of the association and dissociation phases for different con-
centrations of TVASS indicated the binding of two com-
ponents to PAI-1-Ala335Glu. One of the two components
bound to the protein with an association rate constant of
approximately ≥ 70 M–1 s–1, whereas the second compo-
nent bound with an association rate of 1 M–1 s–1, as esti-
mated from the global analysis model consisting of two
independent binding sites. However, because of the high
concentration of TVASS needed to detect the more
slowly associating component, there were too few data
points available during the rapid binding phase to allow a
detailed analysis of the association phase of this component
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Figure 5
Stereo view of the second binding site
domain for TVASS in PAI-1-Ala335Glu. All
residues in the neighbouring β strands within
4 Å of TVASS are pictured. TVASS is shown
in purple ball-and-stick representation. The
possible hydrogen bonds are indicated with
red dashed lines. The two water molecules
near TVASS are also included, with the
hydrogens oriented to obtain an optimal
hydrogen-bond network.
Figure 6
Stereo view of the electron-density map
(Fo–Fc map, contoured at 3σ) showing the
first three residues of one of the two identified
glycan molecules. The blue ribbons represent
the protein backbone structure in the
surrounding region.
His 261 His 261
Phe 213 Phe 213
Asn 265 Asn 265
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(Figure 9). Another complicating factor is the large contri-
bution of the shift in refractive index due to the high con-
centration of TVASS. An excellent least-squares fit was, on
the other hand, obtained for the dissociation phase with two
independent components in the model, showing nearly
equal amplitudes with rate constants of 7 × 10–3 and
7 × 10–4 s–1. This is consistent with two binding sites with
KDs of ≤ 100 µM and 700 µM, respectively. Attempts to
isolate the rapid binding phase by utilising lower TVASS
concentrations did not improve on the accuracy as a result
of an inherently bad signal-to-noise ratio, although these
experiments also indicated a KD in the range of 10–100 µM
for the more rapidly binding component.
Properties of the two binding sites for TVASS
In latent PAI-1, residues P16–P4, SGTVASSSTAVIV, is
inserted in β sheet A. In our model of the complex, the
first molecule of TVASS is perfectly situated in the same
space as P14–P10 in cleaved and latent PAI-1. The second
molecule of TVASS is unexpectedly found in the same
space as Ala340–Ala345 (P6–P2) in cleaved PAI-1-Ala335Pro
(Figure 5). In our complex, the N-acetyl group of TVASS
thus replaces Ala340 of cleaved and latent PAI-1 and the
valine residue in TVASS makes a new van der Waals
contact with Val157. Moreover, two new hydrogen bonds
were formed with the C-terminal serine residue in TVASS,
one from the NH2 to the carbonyl moiety of Leu160 and
one from the Oγ group to the carbonyl oxygen group of
Glu313. Furthermore, the salt-bridge between residues
Glu313 and Arg162 is still present in this complex.
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Figure 7
Ramachandran plot of the PAI-1-Ala335Glu–peptide complex based
on the final refined model. Glycine residues are represented by
triangles, all non-glycine residues are shown as squares. The shaded
areas represent, going from darkest to lightest shading, the
gradation from allowed to disallowed regions. Of the residues, 92%
are in the most favoured regions and only one residue is in the
disallowed region. (The figure was produced using the program
PROCHECK [36].)
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Figure 8
Affinity of tPA for immobilised PAI-1-Ala335Glu. BIAcore sensorgram
illustrating binding and dissociation of tPA; the flow rate of the buffer
was 5 µl min–1 and the temperature 37°C. At arrow ‘A’, 30 nM tPA was
injected over the surface of amine-coupled PAI-1-Ala335Glu. At arrow
‘B’, the protein was replaced by buffer. The PAI-1 surfaces were
pretreated with 1 mM TVASS (solid line) or buffer (dashed line) for
14 min before injection of tPA.
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Figure 9
The binding of TVASS to immobilised PAI-1-Ala335Glu. BIAcore
sensorgram illustrating the binding and dissociation of TVASS; the
flow rate of the buffer was 5 µl min–1 and the temperature 25°C. At
arrow ‘A’, 1 mM TVASS was injected over the surface of amine-
coupled PAI-1-Ala335Glu (14 kRU). At arrow ‘B’, the peptide was
replaced by buffer. Using BIAevaluation the sensorgram was corrected
for the change in RU caused by injection of TVASS on a reference
surface without immobilised protein.
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It is, of course, an open question which of the two
binding sites has the highest affinity for TVASS. More-
over, it is uncertain if we can completely exclude cooper-
ativity, or sequential binding. One way to distinguish the
two sites would be to design peptides, or peptide-like
molecules, with strong preferences for one of the two
sites and then measure the binding kinetics of TVASS in
the presence of this site-specific ligand. Another option
would be to design mutants in which either of these two
binding sites are altered.
Biological implications
Serine protease inhibitors (serpins) are a group of more
than 40 proteins, many of which have important regula-
tory functions in the human body. The inhibitory serpin
plasminogen activator inhibitor type 1 (PAI-1) inacti-
vates tissue plasminogen activator (tPA) and thus attenu-
ates the human fibrinolytic system. It is highly likely that
an elevated level of PAI-1 is associated with the develop-
ment and progression of thromboembolic diseases in man
[28]. Reduction of PAI-1 activity, for example by using
inhibitory antibodies, has been shown to enhance the dis-
solution of blood clots both in vitro and also in experimen-
tal models of thrombosis in vivo. These results have
created an interest in the development of therapeutically
useful low molecular weight PAI-1 inhibitors.
Inhibitory serpins, such as antithrombin, antiplasmin and
PAI-1, act by trapping their target enzymes in covalent,
inactive complexes. So far, no crystal structure of a
serpin–protease complex has been deduced, but evidence
from serpin crystal structures as well as studies of serpin
mutants have been used to formulate a hypothesis for the
mechanism of serpin action. During complex formation
with the target protease, the reactive-centre loop of the
serpin is believed to undergo a large structural rearrange-
ment which takes it from being exposed on the surface of
the protein to being inserted as the integral β strand 4A in
the β sheet A. Obstruction of this loop insertion has been
shown to be a way of transforming a serpin from an
inhibitor into a substrate for its target enzyme. 
Great effort has been devoted to crystallising the thermo-
dynamically unstable active conformation of PAI-1, but
without success. Instead, because it has been shown previ-
ously that fragments of the reactive-centre loop can inter-
fere with the inhibitory function of PAI-1, we have
focused on crystallising the complex of such a peptide with
a stable mutant of this protein. We present here the 1.95 Å
X-ray structure of the complex of PAI-1-Ala335Glu and
two molecules of the loop pentapeptide N-Ac-TVASS-
NH2. This is the first reported crystal structure of a
complex formed between a serpin and a serpin inhibitor.
This structure also has one of the highest resolutions for a
serpin structure. These data strongly support the hypothe-
sis that molecules occupying the space between the
β strands 3A and 5A of a serpin, thereby preventing the
reactive-centre loop from being inserted into β sheet A,
have the potential to convert a serpin from an inhibitor
into a substrate for their target enzyme.
Finally, either or both of the two N-Ac-TVASS-NH2-
binding cavities constitute interesting target sites for
computer-aided design of novel and potent low molecular
weight inhibitors of PAI-1. Such inhibitors may be of
potential use in the prevention of thromboembolic dis-
eases.
Materials and methods
Peptides and proteins
TVASS, N-Ac-Thr-Val-Ala-Ser-Ser-NH2 (AR-H038805XX) was synthe-
sised at Astra Hässle AB (Mölndal, Sweden). Wild-type human PAI-1
and the PAI-1-Ala335Glu mutant from the medium of Chinese hamster
ovary cells were constructed, purified and activated as described
previously [16,29]. Two-chain tPA from human melanoma cells was
obtained from Biopool (Umeå, Sweden). The protein concentration of
the ultracentrifuged protein solutions of PAI-1 and tPA was determined
using the previously determined ε280 [27]. The proteins were stored
and handled as previously described [12].
Crystallisation and data collection
Many years of efforts to obtain crystals from active PAI-1, or active
PAI-1 in complex with different inhibitors and antibodies, have up to
now been without results, probably because of the inherent lability of
this form of PAI-1. We have therefore chosen instead to crystallise
the exceptionally stable PAI-1 mutant PAI-1-Ala335Glu [16]. In the
presence of TVASS, two crystal forms of PAI-1-Ala335Glu were
obtained at 20°C by utilising the hanging drop vapour diffusion tech-
nique, one in 8% PEG 8000 solution using 0.1 M Tris-HCl buffer at
pH 8.5 (form I), and the second in 2.0 M sodium formate, 0.1 M
sodium acetate, pH 4.6 (form II). In both cases 5 µl of 14 mg ml–1
PAI-1-Ala335Glu in 10 mM HEPES buffer, 0.1 M NaCl at pH 7.0,
containing 1 mM TVASS, were diluted with 5 µl reservoir solution
without additives. Both crystal forms belonged to two closely related
orthorhombic unit cells of identical space group P212121, but with
slightly different cell constants: form I, a = 61.36 Å, b = 80.12 Å, c
= 98.68 Å, α = β = γ = 90°; and form II, a = 63.12 Å, b = 83.37 Å,
c = 101.78 Å, α = β = γ = 90°. The X-ray data to 1.95 Å resolution
was collected from crystal form II on a Rigaku (MSC) R-AXIS II image
plate (IP) diffractometer system using CuKα radiation from a rotating
anode. Data collection and refinement statistics are presented in
Table 1. The data were reduced and scaled using the DENZO [30]
and SCALEPACK [31] programs.
Structure solution and refinement
For the continuing structure-solution analysis the X-ray data from set IIb
was used. The crystal structure of PAI-1-Ala335Glu was solved by mol-
ecular replacement using the program AMORE as distributed with the
CCP4 program package [32]. The structure of latent non-glycosylated
PAI-1 [17] was subsequently used as the search model and one clear
solution from the rotation and translation function analysis was easily
found. In the rotation function calculation, the top peak was 6.7σ above
mean, while the second highest peak was only 4.1σ. The translation
function calculation based on the result from the rotation function
analysis resulted in one major peak and this solution was then sub-
jected to a Fourier map calculation and visually inspected. The solution
gave an electron-density map which showed clear protein boundaries
but fewer visible details inside the protein molecule, that is with the
secondary structure elements not well defined. Subsequent phase
improvement using the DM program, distributed with the CCP4 suite
[33], resulted in a much improved map quality and the secondary struc-
ture of the molecule was at this point then easily interpretable. Iterative
cycles of model building using program O [34] interspersed with
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regular refinement cycles using XPLOR [35] gave R/Rfree values of
0.205/0.253 for diffraction data between 7.0 and 1.95 Å resolution.
Additional refinement with the bulk solvent correction included in
XPLOR resulted in R/Rfree values of 0.181/0.210 for data between
40.0 and 1.95 Å. The rms deviations of the bond lengths and bond
angles from ideal geometry were 0.007 Å and 1.366°, respectively. The
overall geometry of the model is excellent, as judged from the output of
PROCHECK [36], and the overall G factor of 0.3 is well above the
typical value of –0.3.
Surface plasmon resonance
A BIAcore 2000 analytical system equipped with a CM5 sensor chip
and the analytical software for evaluation of the kinetics (BIAevaluation
3.0), all from BIAcore AB, was used in these analyses. Proteins were
immobilised via primary amine groups to the dextran surface, as previ-
ously described [28]. Surface densities of immobilised proteins were
chosen to comply with the desired requirements. All BIAcore-analyses
were performed at a flow rate of 5 µl min–1 in a buffer from BIAcore AB
consisting of 10 mM HEPES, 150 mM NaCl, 3.4 mM EDTA and
0.005% P 20. The theory for the evaluation of the kinetic constants has
previously been described [12]. By simulating the kinetic experiments it
was verified, using the BIAsimulation software, that mass transport was
of no importance in these experiments. The response was expressed in
resonance units, RU.
For the determination of the substrate behaviour of PAI-1 by BIAcore
at 37°C, the same large densities of PAI-1-Ala335Glu (18 kRU) were
immobilised on two different sensor chip surfaces. In parallel, 1 mM
TVASS or buffer was injected over the two surfaces for 14 min. Then
30 nM tPA was injected over both surfaces and the association and
dissociation phases were followed. In a separate control experiment
tPA was injected over a surface which was activated and deactivated
in the absence of PAI-1.
To monitor the binding kinetics of TVASS, four surfaces with the same
high density of immobilised PAI-1-Ala335Glu (14 kRU) were first equili-
brated overnight with buffer at 25°C. Thereafter, each surface was
exposed to a specific concentration of TVASS (0.5, 1, 2 or 4 mM) and
the association and dissociation phases were followed. As a control,
4 mM TVASS was also injected in the absence of PAI-1 to exclude
interference with the sensor surface.
SDS–PAGE
The SDS–PAGE was performed as previously described [37] on
PhastGel Gradient 8–25% gels with a PhastSystem electrophoresis
unit, and the evaluation of the stained gels was performed with an
ImageMaster densitometer, all obtained from Pharmacia Biotech AB.
Mass spectrometry
Mass spectra were recorded using a Finnigan TSQ 700 triple quadru-
pole mass spectrometer equipped with a Finnigan electrospray ion
source [8] or a MALDI spectrometer from PerCeptive Biosystems,
Voyager Elite, using a Sinapinic acid matrix. Immediately before record-
ing the spectra, a buffer exchange of the proteins was performed on a
NAP-5 column (Pharmacia Biotech) equilibrated in 1% acetic acid/
water (v/v). The mass spectrometers were calibrated in the high mass
range using myoglobin and PEG 2000.
Accession numbers
The coordinates have been deposited in the Brookhaven Protein Data
Bank with accession code 1A7C.
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